HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis.

AuthorsPeter Mollee, Campbell Tiley, Ilona Cunningham, John Moore, H Miles Prince, Paul Cannell, Steve Gibbons, Jill Tate, Sanjoy Paul, Helen Mar Fan, Devinder S Gill
JournalBritish journal of haematology (Br J Haematol) Vol. 157 Issue 6 Pg. 766-9 (Jun 2012) ISSN: 1365-2141 [Electronic] England
PMID22390735 (Publication Type: Clinical Trial, Phase II, Letter, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents, Alkylating
  • Melphalan
Topics
  • Adolescent
  • Adult
  • Aged
  • Amyloidosis (drug therapy, mortality)
  • Antineoplastic Agents, Alkylating (administration & dosage, adverse effects)
  • Female
  • Humans
  • Melphalan (administration & dosage, adverse effects)
  • Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: